STTK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States...

Stats
Today's Volume	40 019.00
Average Volume	53 798.00
Market Cap	84.97M
EPS	$0 ( 2023-11-14 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.890
ATR14	$0.0540 (2.68%)

Insider Trading

Date	Person	Action	Amount	type
2023-05-26	Redmile Group, Llc	Buy	40 258	Stock Option (Right to Buy)
2023-05-26	Lee Michael Stewart	Buy	40 258	Stock Option (Right to Buy)
2023-05-26	Boudreau Helen M	Buy	40 258	Stock Option (Right to Buy)
2023-05-26	Golumbeski George	Buy	40 258	Stock Option (Right to Buy)
2023-05-26	Gibson Neil W	Buy	40 258	Stock Option (Right to Buy)

INSIDER POWER
53.74
Last 99 transactions
Buy: 1 930 617 \| Sell: 932 277

Shattuck Labs, Inc. Correlation

10 Most Positive Correlations
IPDN	0.931
RMRM	0.926
PALT	0.919
PAIC	0.914
APOP	0.897
SOFIW	0.897
SVAC	0.896
PRCH	0.894
AMAO	0.89
STX	0.888

10 Most Negative Correlations
MMAC	-0.935
NETE	-0.917
BOCH	-0.91
AMRB	-0.9
DTSS	-0.854
CFV	-0.849
AZTA	-0.833
BCYC	-0.826
EAR	-0.826
AKAM	-0.824

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Shattuck Labs, Inc. Financials

Annual	2022
Revenue:	$652 000
Gross Profit:	$652 000 (100.00 %)
EPS:	$-2.37

Q3	2023
Revenue:	$686 000
Gross Profit:	$686 000 (100.00 %)
EPS:	$-0.650

Q2	2023
Revenue:	$200 000
Gross Profit:	$200 000 (100.00 %)
EPS:	$-0.500

Q1	2023
Revenue:	$57 000.00
Gross Profit:	$57 000.00 (100.00 %)
EPS:	$-0.470

Shattuck Labs, Inc.

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.